Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0N8ZM)

• Drug Name: Coumarin Drug Info
• Synonyms: coumarin; 2H-Chromen-2-one; 91-64-5; 2H-1-Benzopyran-2-one; cumarin; 1,2-Benzopyrone; Rattex; Tonka bean camphor; Coumarinic anhydride; chromen-2-one; Coumarine; Benzo-alpha-pyrone; cis-o-Coumarinic acid lactone; o-Hydroxycinnamic acid lactone; o-Hydroxycinnamic lactone; 2-Oxo-1,2-benzopyran; Coumarinic lactone; Kumarin; Benzo-a-pyrone; Kumarin [Czech]; 5,6-Benzo-2-pyrone; 2H-1-Benzopyran, 2-oxo-; 5,6-Benzo-alpha-pyrone; 2H-Benzo(b)pyran-2-one; 2H-Benzo[b]pyran-2-one; Caswell No. 259C; o-Coumaric acid lactone

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 323
  ChEBI ID: CHEBI:28794
  CAS Number: CAS 91-64-5
  TTD Drug ID: DM0N8ZM
  VARIDT Drug ID: DR00864
  INTEDE Drug ID: DR0386

Molecule-Related Drug Atlas

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Premature labour	JB00	Approved	[6]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[7]
Estradiol	DMUNTE3	Breast cancer	2C60-2C65	Approved	[8]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[9]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[9]
Verapamil	DMA7PEW	Hypertension	BA00-BA04	Approved	[11]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[12]
Estrone	DM5T6US	Menopausal and postmenopausal disorder	GA30	Approved	[13]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[14]

Drug(s) Metabolized By Cytochrome P450 102D1 (cyp102)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daidzein	DMRFTJX	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[15]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[16]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[21]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[18]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[15]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[22]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[22]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[23]
Acetazolamide	DM1AF5U	Glaucoma/ocular hypertension	9C61	Approved	[22]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[24]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[15]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[25]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[18]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[17]
GALLICACID	DM6Y3A0	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[15]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[25]
Dorzolamide	DMA17D0	Open-angle glaucoma	9C61	Approved	[26]
Chlorothiazide	DMLHESP	Congestive heart failure	BD10	Approved	[27]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[28]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[28]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[29]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[30]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[31]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[32]
Trientine	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[21]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]
Spermine	DMD4BFY	N. A.	N. A.	Terminated	[21]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[18]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[33]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[16]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[34]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Phentermine+topiramate	DMVEHM4	Obesity	5B81	Phase 3	[35]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[36]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Seborrhoeic dermatitis	EA81	Approved	[15]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[37]
Brinzolamide	DMBAPFG	Open-angle glaucoma	9C61	Approved	[22]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[38]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[36]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[17]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[18]
Phenol	DM1QSM3	N. A.	N. A.	Phase 2/3	[17]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[19]
Indisulam	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[39]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[40]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[41]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[42]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[43]
Ferulic Acid	DMJC7NF	Discovery agent	N.A.	Patented	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[2]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[2]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[1]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[1]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[1]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[1]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[1]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[3]
Cytochrome P450 102D1 (cyp102)	DEUWAV0	CPXB_BACMB	Substrate	[4] , [5]

References

• [1] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [2] 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
• [3] Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017 Dec 28;8(1).
• [4] The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
• [5] Cloning, expression and characterization of CYP102D1, a self-sufficient P450 monooxygenase from Streptomyces avermitilis. FEBS J. 2012 May;279(9):1650-62.
• [6] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [7] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [8] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [9] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [10] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [11] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [12] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [13] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [14] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [15] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [16] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [17] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [18] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [19] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [20] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [21] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [22] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [24] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [25] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [26] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [27] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [28] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [29] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [30] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [31] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [32] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [33] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [34] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [35] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [36] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [37] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [38] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [39] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [40] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [41] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [42] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [43] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.